Aquestive Therapeutics, Inc.
AQSTDrugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Aug 11, 2026
6dMarket Overview
Stock performance and key metrics
1 upcoming, 1 past
AQST Earnings Report
EPS Est: $-0.10 | FQ end 2026-06 | Call: 2026-08-12 15:00:00
How AQST's past catalysts played out
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category
Epilepsy
Diazepam Buccal Film 12.5 mg
Epilepsy
Diazepam Buccal Film
Epilepsy
Diastat® Rectal Gel (Valeant Pharmaceuticals USA)
Epilepsy
DESF
Allergic Reaction
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category | Phase 3 | Epilepsy | - | - |
Diazepam Buccal Film 12.5 mg | Phase 2 | Epilepsy | - | - |
Diazepam Buccal Film | Phase 2 | Epilepsy | - | - |
Diastat® Rectal Gel (Valeant Pharmaceuticals USA) | Phase 2 | Epilepsy | - | - |
DESF | Phase 2 | Allergic Reaction | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Aquestive Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Aquestive Therapeutics, Inc.'s (AQST) pipeline across Phase 3, Phase 2. Its lead program is Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Aquestive Therapeutics, Inc.'s next FDA catalyst?→
Aquestive Therapeutics, Inc.'s (AQST) next tracked catalyst is a Earnings expected August 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track AQST biotech catalysts?→
Add AQST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Aquestive Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.